Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.45 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 7/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641771 | 0.88 | MAPT (0.43) | METTL3METTL14F10ENPP2MAPT | |
| SCHEMBL5641069 | 0.83 | ENPP2 (0.37) | CHRNA7FAAHENPP2MAPTLMNA | |
| SCHEMBL5641386 | 0.83 | METTL3 (0.57) | METTL3METTL14F10MAPTHPGD | |
| SCHEMBL4587753 | 0.81 | PRMT5 (0.54) | F10PRMT5GFERMAPTHSD17B10 | |
| SCHEMBL4586513 | 0.79 | BCHE (0.50) | F10PRMT5GFERMAPTHSD17B10 | |
| SCHEMBL5641236 | 0.78 | F10 (0.38) | F10CHRNA7FAAHMAPTLMNA | |
| SCHEMBL4587417 | 0.77 | F10 (0.51) | METTL3METTL14F10MAPTHSD17B10 | |
| SCHEMBL5637612 | 0.76 | F10 (0.51) | METTL3METTL14F10PRMT5CHRNA7 | |
| SCHEMBL4588040 | 0.76 | METTL3 (0.56) | METTL3METTL14F10MAPTHPGD | |
| SCHEMBL5640731 | 0.76 | CCR3 (0.50) | PRMT5MAPTHSD17B10LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | METTL3 4877/4885METTL14 4795/4885F10 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.